San Francisco, California, USA, Oct. 25, 2023 (GLOBE NEWSWIRE) -- US Capital Global Securities LLC, an affiliate of US Capital Global, recently launched an investment opportunity of up to $5 million in Canadian health science pioneer Andira Pharmaceuticals (“Andira” or the “Company”). Andira, a private pharmaceutical development company dedicated to improving lives and addressing critical illnesses, has announced a significant milestone in the fight against breast cancer.

2023年10月25日，美国加利福尼亚州旧金山（GLOBE NEWSWIRE）-美国首都全球的子公司美国首都全球证券有限责任公司最近在加拿大卫生科学先驱Andira制药公司（“Andira”或“公司”）。安迪拉是一家致力于改善生活和解决重大疾病的私营制药开发公司，已宣布在抗击乳腺癌方面取得重大里程碑。

Andira’s Founder and CEO, Dr. Dana Lambert, revealed, “The Company has achieved extraordinary validation of the efficacy of our lead breast cancer formula, XOXO4, at the University of British Columbia.” The groundbreaking research results demonstrate successful regression of human breast cancer tumors following topical treatment with XOXO4, a cannabinoid formula, in a particular model of breast cancer.

Andira的创始人兼首席执行官Dana Lambert博士透露：“该公司在不列颠哥伦比亚大学对我们的主要乳腺癌配方XOXO4的功效进行了非凡的验证。”开创性的研究结果表明，局部用大麻素配方XOXO4治疗后，人乳腺癌肿瘤成功消退，在特定的乳腺癌模型中。

Equally significant, the latest research results also reveal that XOXO4 outperformed all eight FDA-approved breast cancer-specific chemotherapy drugs included in the study and showed greatly improved cancer-fighting effects when combined with approved breast cancer treatments. North American women have a 1 in 8 chance, or 12.9 percent lifetime risk, of being diagnosed with breast cancer.

同样重要的是，最新的研究结果还显示，XOXO4优于研究中包含的所有8种FDA批准的乳腺癌特异性化疗药物，并且与批准的乳腺癌治疗相结合时显示出极大改善的抗癌效果。北美女性被诊断患有乳腺癌的几率为八分之一，即终生风险的12.9%。

The US-based National Breast Cancer Center reports in 2020 that 685,000 people died from breast cancer worldwide, more than one person per minute. The primary cause of death in breast cancer patients is the development of lethal metastatic lesions, which occur when cancer cells from the primary tumor spread and grow at distant sites in the body.

2020年，美国国家乳腺癌中心报告说，全世界有685000人死于乳腺癌，每分钟超过一人。乳腺癌患者死亡的主要原因是致死性转移性病变的发展，当来自原发性肿瘤的癌细胞在体内远处扩散和生长时发生。

Andira Pharmaceuticals, driven by a mission to leverage natural drug substances to enhance healthcare outcomes, is advancing urgently needed solutions across three critical are.

安迪拉制药公司在利用天然药物物质提高医疗保健成果的使命的推动下，正在推进三个关键领域迫切需要的解决方案。

Attachment

附件

Andira Pharmaceuticals Achieves Remarkable Breast Cancer Tumor Regression with Lead Oncology Candidate XOXO4

Andira Pharmaceuticals通过领先的肿瘤候选药物XOXO4实现了显着的乳腺癌肿瘤消退